{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:11:30Z","timestamp":1791223890506,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.encep.2013.12.002","type":"journal-article","created":{"date-parts":[[2014,1,18]],"date-time":"2014-01-18T17:57:11Z","timestamp":1390067831000},"page":"62-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacit\u00e9 de l\u2019aripiprazole dans le traitement de la schizophr\u00e9nie\u00a0: quelle dose pour quel effet\u00a0?"],"prefix":"10.1016","volume":"40","author":[{"given":"T.","family":"Charpeaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-M.","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.encep.2013.12.002_bib0005","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1371\/journal.pmed.0030327","article-title":"Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia","volume":"3","author":"Holmes","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.encep.2013.12.002_bib0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jad.2012.02.029","article-title":"Pharmacotherapy challenges in patients with first-episode psychosis","volume":"138\u00a0Suppl.","author":"Abdel-Baki","year":"2012","journal-title":"J Affect Disord"},{"issue":"1\u20133","key":"10.1016\/j.encep.2013.12.002_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","article-title":"World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr Res"},{"issue":"9","key":"10.1016\/j.encep.2013.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1176\/appi.ajp.157.9.1379","article-title":"Depression in schizophrenia: perspective in the era of \u201catypical\u201d antipsychotic agents","volume":"157","author":"Siris","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2013.12.002_bib0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.encep.2013.12.002_bib0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","article-title":"Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile","volume":"18","author":"Hirose","year":"2004","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.encep.2013.12.002_bib0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.encep.2013.12.002_bib0040","first-page":"CD004578","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.encep.2013.12.002_bib0045","first-page":"CD006617","article-title":"Aripiprazole versus typicals for schizophrenia","author":"Bhattacharjee","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.encep.2013.12.002_bib0050","first-page":"CD006622","article-title":"Aripiprazole versus placebo for schizophrenia","author":"Belgamwar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.encep.2013.12.002_bib0055","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.emcps.2005.01.001","article-title":"Pharmacologie et mode d\u2019action des neuroleptiques","volume":"2","author":"Franck","year":"2005","journal-title":"EMC\u00a0\u2013\u00a0Psychiatrie"},{"issue":"2","key":"10.1016\/j.encep.2013.12.002_bib0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0447.2005.00736.x","article-title":"Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study","volume":"113","author":"Christensen","year":"2006","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"10.1016\/j.encep.2013.12.002_bib0065","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.comppsych.2012.03.003","article-title":"Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study","volume":"53","author":"Guo","year":"2012","journal-title":"Compr Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.encep.2013.12.002_bib0070","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0165-0327(11)70003-9","article-title":"Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder","volume":"128","author":"Blier","year":"2011","journal-title":"J Affect Disord"},{"issue":"5\u00a0Suppl. 9","key":"10.1016\/j.encep.2013.12.002_bib0075","first-page":"1","article-title":"Dosing atypical antipsychotics","volume":"13","author":"Cutler","year":"2008","journal-title":"CNS Spectr"},{"issue":"12","key":"10.1016\/j.encep.2013.12.002_bib0080","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.encep.2013.12.002_bib0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/JCP.0b013e31818aaf6c","article-title":"Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia","volume":"28","author":"Kinon","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2013.12.002_bib0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2013.12.002_bib0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.encep.2013.12.002_bib0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/13651501.2011.653376","article-title":"Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from india","volume":"17","author":"Jindal","year":"2013","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"11","key":"10.1016\/j.encep.2013.12.002_bib0105","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2013.12.002_bib0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4088\/JCP.v68n0104","article-title":"Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in chinese patients with risperidone as an active control: a randomized trial","volume":"68","author":"Chan","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.encep.2013.12.002_bib0115","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15\u00a0or 20mg\/day for the treatment of patients with acute exacerbations of schizophrenia","volume":"41","author":"McEvoy","year":"2007","journal-title":"J Psychiatr Res"},{"issue":"9","key":"10.1016\/j.encep.2013.12.002_bib0120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S1092852900014784","article-title":"The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia","volume":"11","author":"Cutler","year":"2006","journal-title":"CNS Spectr"},{"issue":"7","key":"10.1016\/j.encep.2013.12.002_bib0125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"10.1016\/j.encep.2013.12.002_bib0130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.encep.2013.12.002_bib0135","first-page":"75","article-title":"The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia","volume":"61","author":"Sato","year":"2012","journal-title":"Hiroshima J Med Sci"},{"issue":"4","key":"10.1016\/j.encep.2013.12.002_bib0140","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.encep.2013.12.002_bib0145","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.encep.2013.12.002_bib0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.encep.2013.12.002_bib0155","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","article-title":"A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia","volume":"65","author":"Fleischhacker","year":"2009","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2013.12.002_bib0160","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/01.pra.0000271658.86845.81","article-title":"Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations","volume":"13","author":"Daniel","year":"2007","journal-title":"J Psychiatr Pract"},{"issue":"11","key":"10.1016\/j.encep.2013.12.002_bib0165","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1185\/030079906X148445","article-title":"Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study","volume":"22","author":"Andrezina","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.encep.2013.12.002_bib0170","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4088\/JCP.v68n0503","article-title":"Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post-hoc analysis of 4\u00a0randomized, placebo-controlled clinical trials","volume":"68","author":"Marder","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2013.12.002_bib0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/cap.2008.0163","article-title":"Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post-hoc analysis of randomized clinical trial data","volume":"20","author":"Robb","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.encep.2013.12.002_bib0180","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jpsychires.2010.09.003","article-title":"Aripiprazole versus haloperidol treatment in early-stage schizophrenia","volume":"45","author":"Girgis","year":"2011","journal-title":"J Psychiatr Res"},{"issue":"1\u20133","key":"10.1016\/j.encep.2013.12.002_bib0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.schres.2010.03.040","article-title":"Effect of aripiprazole versus haloperidol on PANSS prosocial items in early-episode patients with schizophrenia","volume":"120","author":"Docherty","year":"2010","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.encep.2013.12.002_bib0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03256145","article-title":"Comparative utility of aripiprazole and haloperidol in schizophrenia: post-hoc analysis of two 52-week, randomized, controlled trials","volume":"7","author":"Kane","year":"2009","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.encep.2013.12.002_bib0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1092852900000249","article-title":"Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol","volume":"14","author":"de Oliveira","year":"2009","journal-title":"CNS Spectr"},{"issue":"7","key":"10.1016\/j.encep.2013.12.002_bib0200","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (STAR) study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2013.12.002_bib0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.12m08001","article-title":"Comparison of long-term safety and effectiveness of 4\u00a0atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization","volume":"74","author":"Jin","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.encep.2013.12.002_bib0210","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00023210-200418090-00005","article-title":"Dose response and atypical antipsychotics in schizophrenia","volume":"18","author":"Kinon","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2013.12.002_bib0215","unstructured":"Aripiprazole\u00a0: r\u00e9sum\u00e9 des caract\u00e9ristiques du produit, http:\/\/www.has-sante.fr\/portail\/jcms\/c_400137\/fr\/abilify"},{"issue":"6","key":"10.1016\/j.encep.2013.12.002_bib0220","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2013.12.002_bib0225","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012\u00a0on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2013.12.002_bib0230","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/JCP.0b013e3182356255","article-title":"Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia","volume":"31","author":"Lin","year":"2011","journal-title":"J Clin Psychopharmacol"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700613002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700613002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T07:26:31Z","timestamp":1538897191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700613002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0013700613002522"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2013.12.002","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 de l\u2019aripiprazole dans le traitement de la schizophr\u00e9nie\u00a0: quelle dose pour quel effet\u00a0?","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2013.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 L\u2019Enc\u00e9phale, Paris. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}